Skip to main content

Publications

  1. de Silva A. Safety of Dengue Vaccine?. Clin Infect Dis. 2023 Jan 13;76(2):371-372. doi: 10.1093/cid/ciac690. PubMed PMID: 36048521.
  2. Adams C, Carbaugh DL, Shu B, Ng TS, Castillo IN, Bhowmik R, Segovia-Chumbez B, Puhl AC, Graham S, Diehl SA, Lazear HM, Lok SM, de Silva AM, Premkumar L. Structure and neutralization mechanism of a human antibody targeting a complex Epitope on Zika virus. PLoS Pathog. 2023 Jan;19(1):e1010814. doi: 10.1371/journal.ppat.1010814. eCollection 2023 Jan. PubMed PMID: 36626401; PubMed Central PMCID: PMC9870165.

  1. de Silva A, White L. Immunogenicity of a Live Dengue Vaccine (TAK-003). J Infect Dis. 2022 Dec 28;227(1):163-164. doi: 10.1093/infdis/jiac424. PubMed PMID: 36285800.
  2. Root HB, Gilleskie M, Lu CH, Gilmore A, Evans M, Nelson BG, Johnson W, Gurney B, Kuruc J, Markmann AJ, Barzin AH, Wohl DA, Fischer WA, Park YA, Weiss S, Napravnik S, Baric R, de Silva AM, Lachiewicz AM, van Duin D, Margolis DM, Herce ME, Bartelt LA. Evaluation of a COVID-19 convalescent plasma program at a U.S. academic medical center. PLoS One. 2022;17(12):e0277707. doi: 10.1371/journal.pone.0277707. eCollection 2022. PubMed PMID: 36480499; PubMed Central PMCID: PMC9731422.
  3. Bartelt LA, Markmann AJ, Nelson B, Keys J, Root H, Henderson HI, Kuruc J, Baker C, Bhowmik DR, Hou YJ, Premkumar L, Cornaby C, Schmitz JL, Weiss S, Park Y, Baric R, de Silva AM, Lachiewicz A, Napravnik S, van Duin D, Margolis DM. Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study. mBio. 2022 Oct 26;13(5):e0175122. doi: 10.1128/mbio.01751-22. Epub 2022 Sep 22. PubMed PMID: 36135380; PubMed Central PMCID: PMC9601237.
  4. Phan TTN, Hvasta MG, Kudlacek ST, Thiono DJ, Tripathy A, Nicely NI, de Silva AM, Kuhlman B. A conserved set of mutations for stabilizing soluble envelope protein dimers from dengue and Zika viruses to advance the development of subunit vaccines. J Biol Chem. 2022 Jul;298(7):102079. doi: 10.1016/j.jbc.2022.102079. Epub 2022 May 26. PubMed PMID: 35643320; PubMed Central PMCID: PMC9249817.
  5. Lopez CA, Cunningham CH, Pugh S, Brandt K, Vanna UP, Delacruz MJ, Guerra Q, Bhowmik DR, Goldstein SJ, Hou YJ, Gearhart M, Wiethorn C, Pope C, Amditis C, Pruitt K, Newberry-Dillon C, Schmitz JL, Premkumar L, Adimora AA, Baric RS, Emch M, Boyce RM, Aiello AE, Fosdick BK, Larremore DB, de Silva AM, Juliano JJ, Markmann AJ. Ethnoracial Disparities in SARS-CoV-2 Seroprevalence in a Large Cohort of Individuals in Central North Carolina from April to December 2020. mSphere. 2022 Jun 29;7(3):e0084121. doi: 10.1128/msphere.00841-21. Epub 2022 May 19. PubMed PMID: 35587682; PubMed Central PMCID: PMC9241523.
  6. Tse LV, Meganck RM, Dong S, Adams LE, White LJ, Mallory ML, Jadi R, de Silva AM, Baric RS. Generation of Mature DENVs via Genetic Modification and Directed Evolution. mBio. 2022 Jun 28;13(3):e0038622. doi: 10.1128/mbio.00386-22. Epub 2022 Apr 28. PubMed PMID: 35481749; PubMed Central PMCID: PMC9239201.
  7. Gallichotte EN, Henein S, Nivarthi U, Delacruz M, Scobey T, Bonaparte M, Moser J, Munteanu A, Baric R, de Silva AM. Vaccine-induced antibodies to contemporary strains of dengue virus type 4 show a mechanistic correlate of protective immunity. Cell Rep. 2022 Jun 7;39(10):110930. doi: 10.1016/j.celrep.2022.110930. PubMed PMID: 35675766; PubMed Central PMCID: PMC9326871.
  8. Narowski TM, Raphel K, Adams LE, Huang J, Vielot NA, Jadi R, de Silva AM, Baric RS, Lafleur JE, Premkumar L. SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people. Cell Rep. 2022 Feb 1;38(5):110336. doi: 10.1016/j.celrep.2022.110336. Epub 2022 Jan 20. PubMed PMID: 35090596; PubMed Central PMCID: PMC8769879.

  1. Medina FA, Vila F, Premkumar L, Lorenzi O, Paz-Bailey G, Alvarado LI, Rivera-Amill V, de Silva A, Waterman S, Muñoz-Jordán J. Capacity of a Multiplex IgM Antibody Capture ELISA to Differentiate Zika and Dengue Virus Infections in Areas of Concurrent Endemic Transmission. Am J Trop Med Hyg. 2021 Dec 20;106(2):585-592. doi: 10.4269/ajtmh.20-1651. PubMed PMID: 34929668; PubMed Central PMCID: PMC8832915.
  2. Adams C, Jadi R, Segovia-Chumbez B, Daag J, Ylade M, Medina FA, Sharp TM, Munoz-Jordan JL, Yoon IK, Deen J, Lopez AL, de Silva AM, Premkumar L. Novel Assay to Measure Seroprevalence of Zika Virus in the Philippines. Emerg Infect Dis. 2021 Dec;27(12):3073-3081. doi: 10.3201/eid2712.211150. PubMed PMID: 34808091; PubMed Central PMCID: PMC8632176.
  3. Nadugala MN, Jeewandara C, Jadi RS, Malavige GN, de Silva AM, Premaratne PH, Goonasekara CL. Natural immunogenic properties of bioinformatically predicted linear B-cell epitopes of dengue envelope and pre-membrane proteins. BMC Immunol. 2021 Nov 3;22(1):71. doi: 10.1186/s12865-021-00462-4. PubMed PMID: 34732126; PubMed Central PMCID: PMC8567598.
  4. González F, Vielot NA, Sciaudone M, Toval-Ruíz C, Premkumar L, Gutierrez L, Cuadra EC, Munguia N, Blandón P, de Silva AM, Rubinstein R, Bowman N, Becker-Dreps S, Bucardo F. Seroepidemiology of SARS-CoV-2 infections in an urban population-based cohort in León, Nicaragua. Epidemiol Infect. 2021 Oct 20;149:e247. doi: 10.1017/S0950268821002144. PubMed PMID: 35172912; PubMed Central PMCID: PMC8674192.
  5. Kudlacek ST, Metz S, Thiono D, Payne AM, Phan TTN, Tian S, Forsberg LJ, Maguire J, Seim I, Zhang S, Tripathy A, Harrison J, Nicely NI, Soman S, McCracken MK, Gromowski GD, Jarman RG, Premkumar L, de Silva AM, Kuhlman B. Designed, highly expressing, thermostable dengue virus 2 envelope protein dimers elicit quaternary epitope antibodies. Sci Adv. 2021 Oct 15;7(42):eabg4084. doi: 10.1126/sciadv.abg4084. Epub 2021 Oct 15. PubMed PMID: 34652943; PubMed Central PMCID: PMC8519570.
  6. Markmann AJ, Giallourou N, Bhowmik DR, Hou YJ, Lerner A, Martinez DR, Premkumar L, Root H, van Duin D, Napravnik S, Graham SD, Guerra Q, Raut R, Petropoulos CJ, Wrin T, Cornaby C, Schmitz J, Kuruc J, Weiss S, Park Y, Baric R, de Silva AM, Margolis DM, Bartelt LA. Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent Individuals. mSphere. 2021 Aug 25;6(4):e0027521. doi: 10.1128/mSphere.00275-21. Epub 2021 Aug 25. PubMed PMID: 34431693; PubMed Central PMCID: PMC8386415.
  7. Bowman NM, Bucardo F, Collins MH, Reyes Y, Centeno Cuadra E, Blette B, Lakshmanane P, Guerra EP, Rubinstein R, Liou GA, de Silva AM, Becker-Dreps S. Clinical and Epidemiological Features of Acute Zika Virus Infections in León, Nicaragua. Am J Trop Med Hyg. 2021 Aug 9;105(4):924-930. doi: 10.4269/ajtmh.20-1191. PubMed PMID: 34370700; PubMed Central PMCID: PMC8592149.
  8. Henein S, Adams C, Bonaparte M, Moser JM, Munteanu A, Baric R, de Silva AM. Dengue vaccine breakthrough infections reveal properties of neutralizing antibodies linked to protection. J Clin Invest. 2021 Jul 1;131(13). doi: 10.1172/JCI147066. PubMed PMID: 34003796; PubMed Central PMCID: PMC8245170.
  9. Daag JV, Ylade M, Adams C, Jadi R, Crisostomo MV, Alpay R, Aportadera ETC, Yoon IK, White L, Deen J, de Silva AM, Lopez AL. Evaluation of a new point-of-care test to determine prior dengue infection for potential use in pre-vaccination screening. Clin Microbiol Infect. 2021 Jun;27(6):904-908. doi: 10.1016/j.cmi.2020.08.026. Epub 2020 Aug 28. PubMed PMID: 32866651.
  10. Segovia-Chumbez B, Graham SD, Jadi R, de Silva AM, Premkumar L. Production of the Receptor-binding Domain of the Viral Spike Proteins from 2003 and 2019 SARS CoVs and the Four Common Human Coronaviruses for Serologic Assays and Inhibitor Screening. Bio Protoc. 2021 May 20;11(10):e4026. doi: 10.21769/BioProtoc.4026. eCollection 2021 May 20. PubMed PMID: 34150933; PubMed Central PMCID: PMC8187116.
  11. González F, Zepeda O, Toval-Ruiz C, Matute A, Vanegas H, Munguia N, Centeno E, Reyes Y, Svensson L, Nordgren J, de Silva AM, Becker-Dreps S, Premkumar L, Bucardo F. Antibody response to SARS-CoV-2 infection over six months among Nicaraguan outpatients. medRxiv. 2021 Apr 29;. doi: 10.1101/2021.04.28.21256122. PubMed PMID: 33948604; PubMed Central PMCID: PMC8095214.
  12. Graham SD, Tu HA, McElvany BD, Graham NR, Grinyo A, Davidson E, Doranz BJ, Diehl SA, de Silva AM, Markmann AJ. A Novel Antigenic Site Spanning Domains I and III of the Zika Virus Envelope Glycoprotein Is the Target of Strongly Neutralizing Human Monoclonal Antibodies. J Virol. 2021 Apr 12;95(9). doi: 10.1128/JVI.02423-20. Print 2021 Apr 12. PubMed PMID: 33597214; PubMed Central PMCID: PMC8104094.
  13. Lopez CA, Cunningham CH, Pugh S, Brandt K, Vanna UP, Delacruz MJ, Guerra Q, Goldstein SJ, Hou YJ, Gearhart M, Wiethorn C, Pope C, Amditis C, Pruitt K, Newberry-Dillon C, Schmitz J, Premkumar L, Adimora AA, Emch M, Boyce R, Aiello AE, Fosdick BK, Larremore DB, de Silva AM, Juliano JJJ, Markmann AJ. Disparities in SARS-CoV-2 seroprevalence among individuals presenting for care in central North Carolina over a six-month period. medRxiv. 2021 Mar 30;. doi: 10.1101/2021.03.25.21254320. PubMed PMID: 33791743; PubMed Central PMCID: PMC8010775.
  14. White LJ, Young EF, Stoops MJ, Henein SR, Adams EC, Baric RS, de Silva AM. Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003). PLoS Negl Trop Dis. 2021 Mar;15(3):e0009258. doi: 10.1371/journal.pntd.0009258. eCollection 2021 Mar. PubMed PMID: 33711074; PubMed Central PMCID: PMC7990299.
  15. Stringer EM, Martinez E, Blette B, Toval Ruiz CE, Boivin M, Zepeda O, Stringer JSA, Morales M, Ortiz-Pujols S, Familiar I, Collins M, Chavarria M, Goldman B, Bowman N, de Silva A, Westreich D, Hudgens M, Becker-Dreps S, Bucardo F. Neurodevelopmental Outcomes of Children Following In Utero Exposure to Zika in Nicaragua. Clin Infect Dis. 2021 Mar 1;72(5):e146-e153. doi: 10.1093/cid/ciaa1833. PubMed PMID: 33515459; PubMed Central PMCID: PMC7935385.
  16. Nivarthi UK, Swanstrom J, Delacruz MJ, Patel B, Durbin AP, Whitehead SS, Kirkpatrick BD, Pierce KK, Diehl SA, Katzelnick L, Baric RS, de Silva AM. A tetravalent live attenuated dengue virus vaccine stimulates balanced immunity to multiple serotypes in humans. Nat Commun. 2021 Feb 17;12(1):1102. doi: 10.1038/s41467-021-21384-0. PubMed PMID: 33597521; PubMed Central PMCID: PMC7889627.
  17. Lopez AL, Adams C, Ylade M, Jadi R, Daag JV, Molloy CT, Agrupis KA, Kim DR, Silva MW, Yoon IK, White L, Deen J, de Silva AM. Determining dengue virus serostatus by indirect IgG ELISA compared with focus reduction neutralisation test in children in Cebu, Philippines: a prospective population-based study. Lancet Glob Health. 2021 Jan;9(1):e44-e51. doi: 10.1016/S2214-109X(20)30392-2. Epub 2020 Nov 16. PubMed PMID: 33212030; PubMed Central PMCID: PMC9358663.
  18. Daag JV, Ylade M, Jadi R, Adams C, Cuachin AM, Alpay R, Aportadera ETC, Yoon IK, de Silva AM, Lopez AL, Deen J. Performance of Dried Blood Spots Compared with Serum Samples for Measuring Dengue Seroprevalence in a Cohort of Children in Cebu, Philippines. Am J Trop Med Hyg. 2021 Jan;104(1):130-135. doi: 10.4269/ajtmh.20-0937. PubMed PMID: 33146119; PubMed Central PMCID: PMC7790110.

  1. Tu HA, Nivarthi UK, Graham NR, Eisenhauer P, Delacruz MJ, Pierce KK, Whitehead SS, Boyson JE, Botten JW, Kirkpatrick BD, Durbin AP, deSilva AM, Diehl SA. Stimulation of B Cell Immunity in Flavivirus-Naive Individuals by the Tetravalent Live Attenuated Dengue Vaccine TV003. Cell Rep Med. 2020 Dec 22;1(9):100155. doi: 10.1016/j.xcrm.2020.100155. eCollection 2020 Dec 22. PubMed PMID: 33377126; PubMed Central PMCID: PMC7762770.
  2. Hou YJ, Chiba S, Halfmann P, Ehre C, Kuroda M, Dinnon KH 3rd, Leist SR, Schäfer A, Nakajima N, Takahashi K, Lee RE, Mascenik TM, Graham R, Edwards CE, Tse LV, Okuda K, Markmann AJ, Bartelt L, de Silva A, Margolis DM, Boucher RC, Randell SH, Suzuki T, Gralinski LE, Kawaoka Y, Baric RS. SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. Science. 2020 Dec 18;370(6523):1464-1468. doi: 10.1126/science.abe8499. Epub 2020 Nov 12. PubMed PMID: 33184236; PubMed Central PMCID: PMC7775736.
  3. Martinez DR, Yount B, Nivarthi U, Munt JE, Delacruz MJ, Whitehead SS, Durbin AP, de Silva AM, Baric RS. Antigenic Variation of the Dengue Virus 2 Genotypes Impacts the Neutralization Activity of Human Antibodies in Vaccinees. Cell Rep. 2020 Oct 6;33(1):108226. doi: 10.1016/j.celrep.2020.108226. PubMed PMID: 33027653; PubMed Central PMCID: PMC7583086.
  4. Mateus J, Grifoni A, Tarke A, Sidney J, Ramirez SI, Dan JM, Burger ZC, Rawlings SA, Smith DM, Phillips E, Mallal S, Lammers M, Rubiro P, Quiambao L, Sutherland A, Yu ED, da Silva Antunes R, Greenbaum J, Frazier A, Markmann AJ, Premkumar L, de Silva A, Peters B, Crotty S, Sette A, Weiskopf D. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science. 2020 Oct 2;370(6512):89-94. doi: 10.1126/science.abd3871. Epub 2020 Aug 4. PubMed PMID: 32753554; PubMed Central PMCID: PMC7574914.
  5. Thomas A, Thiono DJ, Kudlacek ST, Forsberg J, Premkumar L, Tian S, Kuhlman B, de Silva AM, Metz SW. Dimerization of Dengue Virus E Subunits Impacts Antibody Function and Domain Focus. J Virol. 2020 Aug 31;94(18). doi: 10.1128/JVI.00745-20. Print 2020 Aug 31. PubMed PMID: 32611757; PubMed Central PMCID: PMC7459570.
  6. Katzelnick LC, Narvaez C, Arguello S, Lopez Mercado B, Collado D, Ampie O, Elizondo D, Miranda T, Bustos Carillo F, Mercado JC, Latta K, Schiller A, Segovia-Chumbez B, Ojeda S, Sanchez N, Plazaola M, Coloma J, Halloran ME, Premkumar L, Gordon A, Narvaez F, de Silva AM, Kuan G, Balmaseda A, Harris E. Zika virus infection enhances future risk of severe dengue disease. Science. 2020 Aug 28;369(6507):1123-1128. doi: 10.1126/science.abb6143. PubMed PMID: 32855339; PubMed Central PMCID: PMC8274975.
  7. Hou YJ, Okuda K, Edwards CE, Martinez DR, Asakura T, Dinnon KH 3rd, Kato T, Lee RE, Yount BL, Mascenik TM, Chen G, Olivier KN, Ghio A, Tse LV, Leist SR, Gralinski LE, Schäfer A, Dang H, Gilmore R, Nakano S, Sun L, Fulcher ML, Livraghi-Butrico A, Nicely NI, Cameron M, Cameron C, Kelvin DJ, de Silva A, Margolis DM, Markmann A, Bartelt L, Zumwalt R, Martinez FJ, Salvatore SP, Borczuk A, Tata PR, Sontake V, Kimple A, Jaspers I, O’Neal WK, Randell SH, Boucher RC, Baric RS. SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract. Cell. 2020 Jul 23;182(2):429-446.e14. doi: 10.1016/j.cell.2020.05.042. Epub 2020 May 27. PubMed PMID: 32526206; PubMed Central PMCID: PMC7250779.
  8. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, Rawlings SA, Sutherland A, Premkumar L, Jadi RS, Marrama D, de Silva AM, Frazier A, Carlin AF, Greenbaum JA, Peters B, Krammer F, Smith DM, Crotty S, Sette A. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell. 2020 Jun 25;181(7):1489-1501.e15. doi: 10.1016/j.cell.2020.05.015. Epub 2020 May 20. PubMed PMID: 32473127; PubMed Central PMCID: PMC7237901.
  9. Premkumar L, Segovia-Chumbez B, Jadi R, Martinez DR, Raut R, Markmann A, Cornaby C, Bartelt L, Weiss S, Park Y, Edwards CE, Weimer E, Scherer EM, Rouphael N, Edupuganti S, Weiskopf D, Tse LV, Hou YJ, Margolis D, Sette A, Collins MH, Schmitz J, Baric RS, de Silva AM. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci Immunol. 2020 Jun 11;5(48). doi: 10.1126/sciimmunol.abc8413. PubMed PMID: 32527802; PubMed Central PMCID: PMC7292505.
  10. Serrano-Collazo C, Pérez-Guzmán EX, Pantoja P, Hassert MA, Rodríguez IV, Giavedoni L, Hodara V, Parodi L, Cruz L, Arana T, Martínez MI, White L, Brien JD, de Silva A, Pinto AK, Sariol CA. Effective control of early Zika virus replication by Dengue immunity is associated to the length of time between the 2 infections but not mediated by antibodies. PLoS Negl Trop Dis. 2020 May;14(5):e0008285. doi: 10.1371/journal.pntd.0008285. eCollection 2020 May. PubMed PMID: 32463814; PubMed Central PMCID: PMC7255596.
  11. Young E, Carnahan RH, Andrade DV, Kose N, Nargi RS, Fritch EJ, Munt JE, Doyle MP, White L, Baric TJ, Stoops M, DeSilva A, Tse LV, Martinez DR, Zhu D, Metz S, Wong MP, Espinosa DA, Montoya M, Biering SB, Sukulpolvi-Petty S, Kuan G, Balmaseda A, Diamond MS, Harris E, Crowe JE Jr, Baric RS. Identification of Dengue Virus Serotype 3 Specific Antigenic Sites Targeted by Neutralizing Human Antibodies. Cell Host Microbe. 2020 May 13;27(5):710-724.e7. doi: 10.1016/j.chom.2020.04.007. PubMed PMID: 32407709; PubMed Central PMCID: PMC7309352.
  12. Collins MH, Zepeda O, Blette B, Jadi R, Morales M, Pérez R, Liou GA, Montoya-Cruz M, Harris E, Becker-Dreps S, de Silva AM, Stringer J, Bucardo F, Stringer E. Serologic surveillance of maternal Zika infection in a prospective cohort in Leon, Nicaragua during the peak of the Zika epidemic. PLoS One. 2020;15(4):e0230692. doi: 10.1371/journal.pone.0230692. eCollection 2020. PubMed PMID: 32243482; PubMed Central PMCID: PMC7122769.
  13. Tissera HA, Jayamanne BDW, Raut R, Janaki SMD, Tozan Y, Samaraweera PC, Liyanage P, Ghouse A, Rodrigo C, de Silva AM, Fernando SD. Severe Dengue Epidemic, Sri Lanka, 2017. Emerg Infect Dis. 2020 Apr;26(4):682-691. doi: 10.3201/eid2604.190435. PubMed PMID: 32186490; PubMed Central PMCID: PMC7101108.

  1. Andrade DV, Warnes C, Young E, Katzelnick LC, Balmaseda A, de Silva AM, Baric RS, Harris E. Tracking the polyclonal neutralizing antibody response to a dengue virus serotype 1 type-specific epitope across two populations in Asia and the Americas. Sci Rep. 2019 Nov 7;9(1):16258. doi: 10.1038/s41598-019-52511-z. PubMed PMID: 31700029; PubMed Central PMCID: PMC6838341.
  2. Metz SW, Thomas A, Brackbill A, et al. Oligomeric state of the ZIKV E protein defines protective immune responses. Nat Commun. 2019;10(1):4606. Published 2019 Oct 10. doi:10.1038/s41467-019-12677-6
  3. Pérez-Guzmán EX, Pantoja P, Serrano-Collazo C, Hassert MA, Ortiz-Rosa A, Rodríguez IV, Giavedoni L, Hodara V, Parodi L, Cruz L, Arana T, White LJ, Martínez MI, Weiskopf D, Brien JD, de Silva A, Pinto AK, Sariol CA. Time elapsed between Zika and dengue virus infections affects antibody and T cell responses. Nat Commun. 2019 Sep 20;10(1):4316. doi: 10.1038/s41467-019-12295-2. PubMed PMID: 31541110; PubMed Central PMCID: PMC6754404.
  4. Gallichotte EN, Young EF, Baric TJ, et al. Role of Zika Virus Envelope Protein Domain III as a Target of Human Neutralizing Antibodies. MBio. 2019;10(5):e01485-19. Published 2019 Sep 17. doi:10.1128/mBio.01485-19
  5. Grifoni A, Moore E, Voic H, et al. Characterization of Magnitude and Antigen Specificity of HLA-DP, DQ, and DRB3/4/5 Restricted DENV-Specific CD4+ T Cell Responses. Front Immunol. 2019;10:1568. Published 2019 Jul 5. doi:10.3389/fimmu.2019.01568
  6. Collins MH, Tu HA, Gimblet-Ochieng C, et al. Human antibody response to Zika targets type-specific quaternary structure epitopes. JCI Insight. 2019;4(8):e124588. Published 2019 Apr 18. doi:10.1172/jci.insight.124588
  7. Swanstrom JA, Nivarthi UK, Patel B, et al. Beyond Neutralizing Antibody Levels: The Epitope Specificity of Antibodies Induced by National Institutes of Health Monovalent Dengue Virus Vaccines. J Infect Dis. 2019;220(2):219–227. doi:10.1093/infdis/jiz109
  8. Nivarthi UK, Tu HA, Delacruz MJ, et al. Longitudinal analysis of acute and convalescent B cell responses in a human primary dengue serotype 2 infection model. EBioMedicine. 2019;41:465–478. doi:10.1016/j.ebiom.2019.02.060
  9. Andrade P, Gimblet-Ochieng C, Modirian F, et al. Impact of pre-existing dengue immunity on human antibody and memory B cell responses to Zika. Nat Commun. 2019;10(1):938. Published 2019 Feb 26. doi:10.1038/s41467-019-08845-3
  10. Raut R, Corbett KS, Tennekoon RN, et al. Dengue type 1 viruses circulating in humans are highly infectious and poorly neutralized by human antibodies. Proc Natl Acad Sci U S A. 2019;116(1):227–232. doi:10.1073/pnas.1812055115

  1. Grifoni A, Costa-Ramos P, Pham J, et al. Cutting Edge: Transcriptional Profiling Reveals Multifunctional and Cytotoxic Antiviral Responses of Zika Virus-Specific CD8+ T Cells. J Immunol. 2018;201(12):3487–3491. doi:10.4049/jimmunol.1801090
  2. Gallichotte EN, Baric TJ, Nivarthi U, et al. Genetic Variation between Dengue Virus Type 4 Strains Impacts Human Antibody Binding and Neutralization. Cell Rep. 2018;25(5):1214–1224. doi:10.1016/j.celrep.2018.10.006
  3. Metz SW, Thomas A, Brackbill A, et al. Nanoparticle delivery of a tetravalent E protein subunit vaccine induces balanced, type-specific neutralizing antibodies to each dengue virus serotype. PLoS Negl Trop Dis. 2018;12(9):e0006793. Published 2018 Sep 24. doi:10.1371/journal.pntd.0006793
  4. Willcox AC, Collins MH, Jadi R, et al. Seroepidemiology of Dengue, Zika, and Yellow Fever Viruses among Children in the Democratic Republic of the Congo. Am J Trop Med Hyg. 2018;99(3):756–763. doi:10.4269/ajtmh.18-0156
  5. de Silva A.M., Rey F.A., Young P.R., Hilgenfeld R., Vasudevan S.G. (2018) Viral Entry and NS1 as Potential Antiviral Drug Targets. In: Hilgenfeld R., Vasudevan S. (eds) Dengue and Zika: Control and Antiviral Treatment Strategies. Advances in Experimental Medicine and Biology, vol 1062. Springer, Singapore
  6. Gallichotte E.N., Baric R.S., de Silva A.M. (2018) The Molecular Specificity of the Human Antibody Response to Dengue Virus Infections. In: Hilgenfeld R., Vasudevan S. (eds) Dengue and Zika: Control and Antiviral Treatment Strategies. Advances in Experimental Medicine and Biology, vol 1062. Springer, Singapore
  7. Swanstrom JA, Henein S, Plante JA, et al. Analyzing the Human Serum Antibody Responses to a Live Attenuated Tetravalent Dengue Vaccine Candidate. J Infect Dis. 2018;217(12):1932–1941. doi:10.1093/infdis/jiy063
  8. Kudlacek ST, Premkumar L, Metz SW, et al. Physiological temperatures reduce dimerization of dengue and Zika virus recombinant envelope proteins. J Biol Chem. 2018;293(23):8922–8933. doi:10.1074/jbc.RA118.002658
  9. Montoya M, Collins M, Dejnirattisai W, et al. Longitudinal Analysis of Antibody Cross-neutralization Following Zika Virus and Dengue Virus Infection in Asia and the Americas. J Infect Dis. 2018;218(4):536–545. doi:10.1093/infdis/jiy164
  10. Metz SW, Thomas A, White L, et al. Dengue virus-like particles mimic the antigenic properties of the infectious dengue virus envelope. Virol J. 2018;15(1):60. Published 2018 Apr 2. doi:10.1186/s12985-018-0970-2

  11. G.D. Gromowski, S. Henein, C.B. Kannadka, et al. Delineating the serotype-specific neutralizing antibody response to a live attenuated tetravalent dengue vaccine Vaccine, 36 (2018), pp. 2403-2410

  12. Gallichotte EN, Baric TJ, Yount BL Jr, et al. Human dengue virus serotype 2 neutralizing antibodies target two distinct quaternary epitopes. PLoS Pathog. 2018;14(2):e1006934. Published 2018 Feb 26. doi:10.1371/journal.ppat.1006934
  13. Ramasamy V, Arora U, Shukla R, et al. A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice. PLoS Negl Trop Dis. 2018;12(1):e0006191. Published 2018 Jan 8. doi:10.1371/journal.pntd.0006191
  14. Goncalves A, Peeling RW, Chu MC, et al. Innovative and New Approaches to Laboratory Diagnosis of Zika and Dengue: A Meeting Report. J Infect Dis. 2018;217(7):1060–1068. doi:10.1093/infdis/jix678
  15. Premkumar L, Collins M, Graham S, et al. Development of Envelope Protein Antigens To Serologically Differentiate Zika Virus Infection from Dengue Virus Infection. J Clin Microbiol. 2018;56(3):e01504-17. Published 2018 Feb 22. doi:10.1128/JCM.01504-17

  1. Widman DG, Young E, Nivarthi U, et al. Transplantation of a quaternary structure neutralizing antibody epitope from dengue virus serotype 3 into serotype 4. Sci Rep. 2017;7(1):17169. Published 2017 Dec 7. doi:10.1038/s41598-017-17355-5
  2. Liu P, Weinreb V, Ridilla M, et al. Rapid, directed transport of DC-SIGN clusters in the plasma membrane. Sci Adv. 2017;3(11):eaao1616. Published 2017 Nov 8. doi:10.1126/sciadv.aao1616
  3. Grifoni A, Angelo MA, Lopez B, et al. Global Assessment of Dengue Virus-Specific CD4+ T Cell Responses in Dengue-Endemic Areas. Front Immunol. 2017;8:1309. Published 2017 Oct 13. doi:10.3389/fimmu.2017.01309
  4. Grifoni A, Pham J, Sidney J, et al. Prior Dengue Virus Exposure Shapes T Cell Immunity to Zika Virus in Humans. J Virol. 2017;91(24):e01469-17. Published 2017 Nov 30. doi:10.1128/JVI.01469-17
  5. Andrade DV, Katzelnick LC, Widman DG, et al. Analysis of Individuals from a Dengue-Endemic Region Helps Define the Footprint and Repertoire of Antibodies Targeting Dengue Virus 3 Type-Specific Epitopes. MBio. 2017;8(5):e01205-17. Published 2017 Sep 19. doi:10.1128/mBio.01205-17
  6. de Silva AM, Harris E. Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Path to a Dengue Vaccine: Learning from Human Natural Dengue Infection Studies and Vaccine Trials. Cold Spring Harb Perspect Biol. 2018;10(6):a029371. Published 2018 Jun 1. doi:10.1101/cshperspect.a029371
  7. Metz SW, Gallichotte EN, Brackbill A, et al. In Vitro Assembly and Stabilization of Dengue and Zika Virus Envelope Protein Homo-Dimers. Sci Rep. 2017;7(1):4524. Published 2017 Jul 3. doi:10.1038/s41598-017-04767-6
  8. Reller ME, de Silva AM, Miles JJ, et al. Unsuspected Dengue as a Cause of Acute Febrile Illness in Children and Adults in Western Nicaragua. PLoS Negl Trop Dis. 2016;10(10):e0005026. Published 2016 Oct 28. doi:10.1371/journal.pntd.0005026
  9. Patel B, Longo P, Miley MJ, Montoya M, Harris E, de Silva AM. Dissecting the human serum antibody response to secondary dengue virus infections. PLoS Negl Trop Dis. 2017;11(5):e0005554. Published 2017 May 15. doi:10.1371/journal.pntd.0005554
  10. Collins MH, McGowan E, Jadi R, et al. Lack of Durable Cross-Neutralizing Antibodies Against Zika Virus from Dengue Virus Infection. Emerg Infect Dis. 2017;23(5):773–781. doi:10.3201/eid2305.161630
  11. Gallichotte EN, Menachery VD, Yount BL Jr, et al. Epitope Addition and Ablation via Manipulation of a Dengue Virus Serotype 1 Infectious Clone. mSphere. 2017;2(1):e00380-16. Published 2017 Feb 22. doi:10.1128/mSphere.00380-16
  12. Nivarthi UK, Kose N, Sapparapu G, et al. Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination. J Virol. 2017;91(5):e02041-16. Published 2017 Feb 14. doi:10.1128/JVI.02041-16
  13. Henein S, Swanstrom J, Byers AM, et al. Dissecting Antibodies Induced by a Chimeric Yellow Fever-Dengue, Live-Attenuated, Tetravalent Dengue Vaccine (CYD-TDV) in Naive and Dengue-Exposed Individuals. J Infect Dis. 2017;215(3):351–358. doi:10.1093/infdis/jiw576

 

  1. Metz SW, Tian S, Hoekstra G, et al. Precisely Molded Nanoparticle Displaying DENV-E Proteins Induces Robust Serotype-Specific Neutralizing Antibody Responses. PLoS Negl Trop Dis. 2016;10(10):e0005071. Published 2016 Oct 20. doi:10.1371/journal.pntd.0005071
  2. de Silva AM. Ticks Take Cues from Mammalian Interferon. Cell Host & Microbe. 2016;20(1):3-4. Published 2016 Jul 13. doi:10.1016/j.chom.2016.06.016

  3. Lazear HM, Stringer EM, de Silva AM. The Emerging Zika Virus Epidemic in the Americas: Research Priorities. JAMA. 2016;315(18):1945–1946. doi:10.1001/jama.2016.2899

  4. Messer WB, Yount BL, Royal SR, et al. Functional Transplant of a Dengue Virus Serotype 3 (DENV3)-Specific Human Monoclonal Antibody Epitope into DENV1. J Virol. 2016;90(10):5090–5097. Published 2016 Apr 29. doi:10.1128/JVI.00155-16
  5. Smith SA, Nivarthi UK, de Alwis R, et al. Dengue Virus prM-Specific Human Monoclonal Antibodies with Virus Replication-Enhancing Properties Recognize a Single Immunodominant Antigenic Site. J Virol. 2015;90(2):780–789. Published 2015 Oct 28. doi:10.1128/JVI.01805-15
  6. Callaway JB, Smith SA, Widman DG, et al. Source and Purity of Dengue-Viral Preparations Impact Requirement for Enhancing Antibody to Induce Elevated IL-1β Secretion: A Primary Human Monocyte Model. PLoS One. 2015;10(8):e0136708. Published 2015 Aug 24. doi:10.1371/journal.pone.0136708
  7. Weiskopf D, Bangs DJ, Sidney J, et al. Dengue virus infection elicits highly polarized CX3CR1+ cytotoxic CD4+ T cells associated with protective immunity. Proc Natl Acad Sci U S A. 2015;112(31):E4256–E4263. doi:10.1073/pnas.1505956112
  8. Fibriansah G, Ibarra KD, Ng TS, et al. DENGUE VIRUS. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers. Science. 2015;349(6243):88–91. doi:10.1126/science.aaa8651
  9. Callaway JB, Smith SA, McKinnon KP, de Silva AM, Crowe JE Jr, Ting JP. Spleen Tyrosine Kinase (Syk) Mediates IL-1β Induction by Primary Human Monocytes during Antibody-enhanced Dengue Virus Infection. J Biol Chem. 2015;290(28):17306–17320. doi:10.1074/jbc.M115.664136
  10. Gallichotte EN, Widman DG, Yount BL, Wahala WM, Durbin A, Whitehead S, Sariol CA, Crowe JE Jr, de Silva AM, Baric RS (2015)           A new quaternary structure epitope on dengue virus serotype 2 is the target of durable type-specific neutralizing antibodies. MBio. 6(5)
  11. Fibriansah G, Ibarra K, Ng T-S, Smith S, Tan J, Lim, Kostyuchenko VA, Wang, de Silva AM, Harris E, Crowe J, and Lok S. A human antibody that locks dengue virus E protein dimers prevents antibody-enhanced severe disease.  Science. In Press.
  12. Fibriansah G, Tan JL, Smith SA, de Alwis R, Ng T-S, Kostyuchenko VA, Jadi RS, Kukkaro P, de Silva AM, Crowe JE, Lok SM. 2015. A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins. 2015 Nature Communications. 6:6341.
  13. Corbett KS, Katzelnick L, Tissera H, Amerasinghe A, de Silva AD, de Silva AM (2015) Preexisting Neutralizing Antibody Responses Distinguish Clinically Inapparent and Apparent Dengue Virus Infections in a Sri Lankan Pediatric Cohort. Journal of Infectious Diseases 211: 590-599.
  14. Wahala W, de Silva A, Gubler D, Ooi E, Vasudevan S, Farrar J (2014) Dengue virus neutralization and surrogates of protection. Dengue and dengue hemorrhagic fever: 577-589.
  15. Tissera H, Amarasinghe A, De Silva AD, Kariyawasam P, Corbett KS, Katzelnick L, Tam C, Letson GW, Margolis HS, de Silva AM (2014) Burden of dengue infection and disease in a pediatric cohort in urban Sri Lanka. The American journal of tropical medicine and hygiene 91: 132-137.
  16. Smith SA, de Alwis AR, Kose N, Jadi RS, de Silva AM, Crowe JE (2014) Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones. Journal of virology 88: 12233-12241.
  17. Liu P, Wang X, Itano MS, Neumann AK, de Silva AM, Jacobson K, Thompson NL (2014) Low Copy Numbers of DC‐SIGN in Cell Membrane Microdomains: Implications for Structure and Function. Traffic 15: 179-196.
  18. Fibriansah G, Tan JL, Smith SA, de Alwis AR, Ng TS, Kostyuchenko VA, Ibarra KD, Wang J, Harris E, de Silva A, Crowe JE and Lok S. (2014) A potent anti‐dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface. EMBO molecular medicine: e201303404.
  19.  de Alwis R, Williams KL, Schmid MA, Lai C-Y, Patel B, Smith SA, Crowe JE, Wang W-K, Harris E, de Silva AM (2014) Dengue Viruses Are Enhanced by Distinct Populations of Serotype Cross-Reactive Antibodies in Human Immune Sera. PLoS pathogens 10: e1004386.
  20. de Alwis R, de Silva AM (2014) Measuring Antibody Neutralization of Dengue Virus (DENV) Using a Flow Cytometry-Based Technique. Dengue: Springer New York. pp. 27-39.
  21. Zhou Y, Austin SK, Fremont DH, Yount BL, Huynh JP, de Silva AM, Baric RS, Messer WB (2013) The mechanism of differential neutralization of dengue serotype 3 strains by monoclonal antibody 8A1. Virology 439: 57-64.
  22. White LJ, Sariol CA, Mattocks MD, MPB WW, Yingsiwaphat V, Collier ML, Whitley J, Mikkelsen R, Rodriguez IV, Martinez MI (2013) An alphavirus vector-based tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs qualitatively from immunity induced by live virus infection. Journal of virology 87: 3409-3424.
  23. Weiskopf D, Angelo MA, de Azeredo EL, Sidney J, Greenbaum JA, Fernando AN, Broadwater A, Kolla RV, De Silva AD, de Silva AM, Mattia KA, Doranz BJ, Grey HM, Shresta S, Peters B, Sette A. (2013) Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proceedings of the National Academy of Sciences 110: E2046-E2053.
  24. Tissera H, Amarasinge A, de Silva AM (2013) Surveillance of dengue in a community cohort in metropolitan Colombo, Sri Lanka: part I methods and study population. WHO Dengue Bull 37: 141-154.
  25. Tam CC, Tissera H, de Silva AM, De Silva AD, Margolis HS, Amarasinge A (2013) Estimates of dengue force of infection in children in Colombo, Sri Lanka. PLoS neglected tropical diseases 7: e2259.
  26. Smith SA, de Alwis R, Kose N, Durbin AP, Whitehead SS, de Silva AM, Crowe JE (2013) Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics. Journal of Infectious Diseases 207: 1898-1908.
  27. Smith SA, de Alwis AR, Kose N, Harris E, Ibarra KD, Kahle KM, Pfaff JM, Xiang X, Doranz BJ, de Silva AM, Crowe JE (2013) The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein. MBio 4: e00873-00813.
  28. Mani S, Tripathi L, Raut R, Tyagi P, Arora U, Barman T, Sood R, Galav A, Wahala W, de Silva AM, Swaminathan S, Khanna N. (2013) Pichia pastoris-expressed dengue 2 envelope forms virus-like particles without Pre-membrane protein and induces high titer neutralizing antibodies. PloS one 8: e64595.
  29. Williams KL, Wahala WM, Orozco S, de Silva AM, Harris E (2012) Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo. Virology 429: 12-20.
  30. de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WM, White LJ, Diamond MS, Baric RS, Crowe JE, de Silva AM  (2012) Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proceedings of the National Academy of Sciences 109: 7439-7444.